Racial Differences in Natriuretic Peptide Levels. The Dallas Heart Study.

JACC: Heart Failure

Volumn 3, Issue 7, 2015, Pages 513-519

  Gupta, Deepak K ^a   de Lemos, James A ^b   Ayers, Colby R ^b,c   Berry, Jarett D ^b,c   Wang, Thomas J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Deficiency; Hypertension; Natriuretic peptides; Race

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; BLACK PERSON; CARDIOVASCULAR RISK; CAUCASIAN; COHORT ANALYSIS; ETHNICITY; FEMALE; HISPANIC; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; AFRICAN AMERICAN; BLOOD; ETHNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NORMAL HUMAN; STATISTICAL MODEL;

ADULT; AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTHY VOLUNTEERS; HISPANIC AMERICANS; HUMANS; HYPERTENSION; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 84943360576     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.02.008     Document Type: Article

References (45)

1. Wang T.J. The natriuretic peptides and fat metabolism. N Engl J Med 2012, 367:377-378.
2. Mukoyama M., Nakao K., Saito Y., et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 1990, 323:757-758.
3. Gottlieb S.S., Kukin M.L., Ahern D., Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989, 13:1534-1539.
4. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001, 345:1014-1021.
5. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
6. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350:655-663.
7. Mega J.L., Morrow D.A., De Lemos J.A., et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004, 44:335-339.
8. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers and the risk of incident hypertension. Hypertension 2007, 49:432-438.
9. de Lemos J.A., McGuire D.K., Khera A., et al. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. Am Heart J 2009, 157:746-753.e2.
10. Cushman M., Judd S.E., Howard V.J., et al. N-terminal pro-B-type natriuretic peptide and stroke risk: the Reasons for Geographic And Racial Differences in Stroke cohort. Stroke 2014, 45:1646-1650.
11. Tamura N., Ogawa Y., Chusho H., et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000, 97:4239-4244.
12. Wada A., Tsutamoto T., Matsuda Y., Kinoshita M. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 1994, 89:2232-2240.
13. John S.W., Krege J.H., Oliver P.M., et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995, 267:679-681.
14. Melo L.G., Veress A.T., Chong C.K., Ackermann U., Sonnenberg H. Salt-sensitive hypertension in ANP knockout mice is prevented by AT1 receptor antagonist losartan. Am J Physiol 1999, 277:R624-R630.
15. Wang W., Cui Y., Shen J., et al. Salt-sensitive hypertension and cardiac hypertrophy in transgenic mice expressing a corin variant identified in blacks. Hypertension 2012, 60:1352-1358.
16. Krauser D.G., Chen A.A., Tung R., Anwaruddin S., Baggish A.L., Januzzi J.L. Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. J Card Fail 2006, 12:452-457.
17. Montagnana M., Lippi G., Salvagno G.L., Guidi G.C. Reference ranges and diagnostic thresholds of laboratory markers of cardiac damage and dysfunction in a population of apparently healthy black Africans. Clin Chem Lab Med 2008, 46:714-716.
18. Daniels L.B., Clopton P., Potocki M., et al. Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur J Heart Fail 2012, 14:22-31.
19. Choi E.Y., Bahrami H., Wu C.O., et al. N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail 2012, 5:727-734.
20. Lazo M., Young J.H., Brancati F.L., et al. NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes 2013, 62:3189-3193.
21. Victor R.G., Haley R.W., Willett D.L., et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 2004, 93:1473-1480.
22. Deo R., Khera A., McGuire D.K., et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004, 44:1812-1818.
23. Vega G.L., Adams-Huet B., Peshock R., Willett D., Shah B., Grundy S.M. Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab 2006, 91:4459-4466.
24. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
25. Levey A.S., Adler S., Caggiula A.W., et al. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis 1996, 27:652-663.
26. Baber U., de Lemos J.A., Khera A., et al. Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int 2008, 73:615-621.
27. Drazner M.H., Dries D.L., Peshock R.M., et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension 2005, 46:124-129.
28. Das S.R., Drazner M.H., Dries D.L., et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005, 112:2163-2168.
29. Wang T.J., Larson M.G., Levy D., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004, 109:594-600.
30. Melander O., Frandsen E., Magnusson M., Grubb A., Jovinge S., Groop L. NT-proANP in plasma, a marker of salt sensitivity, is reduced in type 2 diabetes patients. J Intern Med 2005, 257:281-288.
31. Wang T.J., Larson M.G., Keyes M.J., Levy D., Benjamin E.J., Vasan R.S. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007, 115:1345-1353.
32. Fox E.R., Musani S.K., Bidulescu A., et al. Relation of obesity to circulating B-type natriuretic peptide concentrations in blacks: the Jackson Heart Study. Circulation 2011, 124:1021-1027.
33. Cheng S., Fox C.S., Larson M.G., et al. Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals. Am J Cardiol 2011, 108:979-984.
34. Khan A.M., Cheng S., Magnusson M., et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab 2011, 96:3242-3249.
35. Newton-Cheh C., Larson M.G., Vasan R.S., et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009, 41:348-353.
36. Wang T.J., Larson M.G., Levy D., et al. Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 2003, 108:13-16.
37. Dries D.L., Victor R.G., Rame J.E., et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation 2005, 112:2403-2410.
38. Lanfear D.E., Stolker J.M., Marsh S., Rich M.W., McLeod H.L. Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther 2007, 21:55-62.
39. Wang W., Liao X., Fukuda K., et al. Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity. Circ Res 2008, 103:502-508.
40. Rame J.E., Drazner M.H., Post W., et al. Corin I555(P568) allele is associated with enhanced cardiac hypertrophic response to increased systemic afterload. Hypertension 2007, 49:857-864.
41. Semenov A.G., Tamm N.N., Seferian K.R., et al. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem 2010, 56:1166-1176.
42. Ehret G.B., Munroe P.B., et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011, 478:103-109. International Consortium for Blood Pressure Genome-Wide Association S.
43. rs2521501 SNP. Available at: . Accessed January 12, 2015. http://useast.ensembl.org/Homo_sapiens/Variation/Explore?db=core;r=15:90893658%1390894658;v=rs2521501;vdb=variation;vf=2159702.
44. McMurray J.J., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014, 371:993-1004.
45. Packer M., McMurray J.J., Desai A.S., et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015, 131:54-61.